Tenaya Therapeutics, Inc.

    Jurisdiction
    United States
    ISIN
    US87990A1060 (TNYA)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    1 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    5 / 7

    Profile

    Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Read full profile

    Fundamentals

    Net revenue
    €0.00
    Gross margin
    0.0%
    EBIT
    -€87.84M
    EBIT margin
    0.0%
    Net income
    -€84.97M
    Net margin
    0.0%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €2.84M +∞% -€84.38M -0.7%
    €136.23M +4,696.4% €2.09M -102.5%
    €417.84M +206.7% €212.94M +10,089.8%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Ali Faraz Chief Executive Officer -15K $1.25 -$18.17K
    Higa Tomohiro SVP, Finance -3K $1.25 -$3.70K
    Tingley Whittemore Chief Medical Officer -5.1K $1.25 -$6.32K

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 1.5M $878.94K +1.2M Buy

    Earnings Calls

    Add to watchlist

    Notifications